Cyclobenzaprine: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Cyclobenzaprine. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Drowsiness | 39% |
| Headache nos | 17% |
| Dry mouth | 14% |
| Dry throat | 8% |
| Dizziness | 6% |
| Dysgeusia | 6% |
| Palpitations | 6% |
| Tremor | 6% |
| Acne nos | 6% |
| Disturbance in attention | 6% |
| Dyspepsia | 4% |
| Fatigue | 3% |
| Constipation | 3% |
| Nausea | 3% |
| Vision blurred | 3% |
| Somnolence | 2% |
| Insomnia | 0% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
AMRIX is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion. AMRIX should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. AMRIX has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsy.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.